BRO · Q1 2026 Earnings
CautiousBrown & Brown
Reported April 27, 2026
30-second summary
Brown & Brown's Q1 FY2026 print landed consolidated organic at 0.0% (2.2% with contingents), with Retail at +1.0% ex-contingents (+1.3% with contingents) and Specialty Distribution at -2.0% ex-contingents (+3.9% with contingents) — a Specialty result that arguably missed the "somewhat flat" Q1 guide on an ex-contingents basis but cleared it with the contingent tailwind. Retail is now absorbing three discrete drags: a $31M annualized litigation-related revenue loss (up from $23M last quarter), faster-than-expected cat property declines, and a newly-disclosed 50–100bps pharmacy consulting headwind to Retail organic that will persist for "the next couple of quarters." Adjusted EBITDAC margin of 38.5% beat the "modest negative Accession impact" guide (Accession was a ~200bps drag, more than offset by underlying expansion and contingents) and the $30–40M FY synergy target was reaffirmed — but the FY retail framing has quietly shifted from "modest improvement over 2.8%" to "modest improvement each quarter vs. Q1," which resets the baseline lower. Specialty Distribution Q2 FY2026 organic ex-contingents was pre-guided to "relatively flat" on heavy cat property weighting.
Headline numbers
EPS
Q1 FY2026
$1.39
Revenue
Q1 FY2026
$1.90B
+35.4% YoY
Free cash flow
Q1 FY2026
$0.24B
Operating margin
Q1 FY2026
28.0%
Key financials
Q1 FY2026| Metric | Q1 FY2026 | YoY | Q4 FY2025 | QoQ |
|---|---|---|---|---|
| Revenue | $1.90B | +35.4% | $1.61B | +18.3% |
| EPS | $1.39 | — | $0.93 | +49.5% |
| Operating margin | 28.0% | — | 20.0% | +800bps |
| Free cash flow | $0.24B | — | — | — |
Guidance
Q1 results beat softened integration concerns; FY2026 accretion synergies reaffirmed, but new pharmacy consulting headwind of 50–100 bps introduced for next quarters.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Actuals vs prior guidance
| Metric | Period | Prior guide | Actual | Δ | Result |
|---|---|---|---|---|---|
| Organic Revenue Growth | Q1 FY2026 | Somewhat flat | 0.0% | in-line | Met |
| Accession Integration Margin Impact | Q1 FY2026 | Modest negative impact on adjusted margins | 38.5% | +40bps above prior year; prior guidance expected negative impact | Beat |
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Organic Revenue Growth (Retail segment - Q2 and beyond) | Q2 FY2026 | Relatively flat, excluding contingents | — |
| Pharmacy Consulting Business Revenue Impact | Q2 FY2026 | Negative 50 to 100 basis points over the next couple of quarters | — |
Changes to prior guidance
| Metric | Period | Prior guide | New guide | Δ | Result |
|---|---|---|---|---|---|
| Organic Revenue Growth - Retail Segment | FY2026 | Modest improvement over 2.8% | Modest improvement each quarter compared to Q1 | qualified improvement; now expects quarter-by-quarter acceleration vs. prior single improvement statement | Raised |
Reaffirmed unchanged this quarter: EBITDAC Margin - Adjusted for Accession ($30 to $40 million)
Segment performance
Q1 FY2026| Segment | Q1 FY2026 | YoY |
|---|---|---|
| Commissions and Fees | $1.88B | +35.6% |
| Organic Revenue | $1.348B | — |
| Organic Revenue with Contingents | $1.422B | +2.2% |
Other KPIs
Q1 FY2026| Segment | Q1 FY2026 |
|---|---|
| EBITDAC - Adjusted | $731 million |
| EBITDAC Margin - Adjusted | 38.5% |
| Income Before Income Taxes Margin | 28.0% |
| Diluted Net Income Per Share - Adjusted | $1.39 |
| Organic Contingents | $74 million |
Management tone
Q1 FY2025 stable softening → Q2 FY2025 cat property decel → Q3 FY2025 organic reset → Q4 FY2025 organic reversal + defensive escalation → Q1 FY2026 AI-first pivot with quantified offsets.
Three quarters ago organic growth was the headline metric; this quarter it has been reframed as transitional with contingents and AI productivity as the structural offsets. In Q2 FY2025 Powell attributed retail miss as half-rate, half-new-business. By Q4 FY2025, management was framing 2.7% retail organic as a problem to be addressed rather than explained away. This quarter the framing escalated to active model redesign: "Generally, when E&S rates are decreasing, our contingents will increase. This inverse correlation creates more stability in our revenues, margins, and cash flow." The rebranding of contingents from cyclical kicker to structural hedge is now complete — and necessary, because consolidated organic landed at 0.0% and would have rendered the print significantly weaker without the $31M YoY contingents tailwind.
AI moved from supporting capability to operating thesis in one quarter. Last quarter's call mentioned technology utilization as one of several drivers of the raised long-term margin band. This quarter Powell put a number on it: "We're scaling AI agents that will automate more than 25% of the end-to-end submission process for many of our programs and wholesale businesses, achieving material cost reductions and removing throughput limits." The shift from aspirational AI language to quantified throughput claims (25% automation, 50k hours saved) is a step-change. Whether this delivers margin compounding or merely offsets organic compression is the central question for the next four quarters.
Accession integration confidence has hardened in two quarters. Two quarters ago integration was being de-risked through cautious language. Last quarter management warned of "modest negative impact on adjusted margins" in Q1 FY2026. This quarter the language is direct: "Integration activities are on track for us to deliver our EBITDA synergies of 30 to 40 million this year. The team's doing a great job and I'm extremely pleased with our progress." The Q1 FY2026 EBITDAC margin beat (38.5% vs. 38.1% PY, with ~200bps Accession drag absorbed) is the proof point. Powell also extended optimism into 2027 — the first explicit forward-year reference on Accession.
The Howden litigation has gotten worse, not better, in the public framing. Q4 FY2025 disclosed $23M of "at present" revenue at risk. This quarter the number was revised to $31M annualized, with $10M hitting Q1 FY2026 and $21M flowing through the rest of the year. The escalation from $23M to $31M in one quarter — quantified on the call rather than buried — suggests further migration has occurred and management is choosing to disclose ahead of the curve. Status remains "this will take a number of quarters to ultimately play itself through."
Property pricing commentary moved from "December surprise" anxiety to disciplined steadiness. Q3 FY2025 introduced Powell's "blue light special" tail-risk scenario; Q4 FY2025 confirmed continued declines. This quarter the language is steadier: "We would not be surprised if in the second quarter, if certain carriers or MGAs become more aggressive related to cat property placements. From our perspective, we will remain disciplined and will not compromise the quality of our underwriting." The reframe to "we won't chase" is healthier underwriting posture but also signals management has accepted ongoing rate pressure rather than calling a turn.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Rob Cox · Goldman Sachs
Questions on the shift from local/regional sales model to specialization model in retail and the revenue model change in specialty pharma from commission to PEPM.
Management clarified that the model is a blend of best practices from both previous approaches, not a move toward larger competitors' models. The specialty pharma revenue model is shifting from volume-based to PEPM over several quarters to better align incentives with helping customers reduce pharmacy spend.
Tracy Bengigu · Wolf Research
Why $25,000 premium threshold for defining small/micro policies; updated guidance on contingent commissions given strong Q1 performance relative to prior $15 million guidance for specialty distribution.
Management defines the threshold at $25,000 based on complexity and customization of middle-market commercial risks. Contingent commissions expected to be higher than the prior $15 million guidance due to outstanding Q1 performance, with comparability to prior year's $255 million and forward variance projections.
Elsie Greenspan · Wells Fargo
Mix of volume-based vs. profit-based contingent commissions; impact of specialty pharma revenue model change on retail organic growth guidance.
Almost all contingent commissions are profit-based with minimal volume component. Management expects retail organic to improve sequentially despite 50-100 bps headwind from specialty pharma model change, driven by sales model improvements and activity increases.
Michael Zarimski · BMO
Update on litigation impact to top line; explanation for organic growth lagging peers despite operational improvements.
Lost business from litigation updated from $23 million annualized to $31 million, with $10 million impact in Q1 flowing across remaining quarters. Organic growth underperformance attributed to: large acquisition integration, startup disruption, property rates down more than expected (one year ahead of schedule), and specialty pharma business issues. Prior to acquisition, specialty distribution had higher weighting to cap property which benefited during tight capacity periods.
Josh Shanker · Bank of America
Florida property market pricing dynamics and variance from national trends; clarification on market concentration for small accounts under $25,000.
Coastal property rates have returned to 2016-17 levels after rising for 5-6 years then declining sharply over 2 years. Rate pressure extends beyond Florida to other cat-prone areas and inland cat/convective storm zones. Example given: SE Florida superior construction condo with sub-20 cent rate consists of 7-8 cents fire rate and remainder all other perils including wind. Small accounts under $25,000 are serviced by independent agents; Brown and Brown focuses on accounts exceeding that threshold.
Answers to last quarter's watch list
What to watch into next quarter
Q2 FY2026 Specialty Distribution organic vs. the "relatively flat" ex-contingents guide — with heavy cat property weighting in Q2; watch whether reported Q2 organic ex-contingents lands flat or slips further negative
Q2 FY2026 Retail organic with the pharmacy 50–100bps drag — guided to modest improvement vs. Q1 FY2026's +1.0% despite the headwind; the offset must come from sales model improvements and activity increases
Litigation-related revenue migration — the $31M annualized has already escalated from $23M at Q4 FY2025; track whether further migration occurs or the $31M holds as the ceiling
FY2026 contingents trajectory — Q1 FY2026's $74M vs. $43M PY puts the FY trajectory materially ahead of the prior "$15M down" Specialty framing; management already flagged total company contingents up YoY — watch for explicit dollar guidance at Q2 FY2026
Adjusted EBITDAC margin in Q2 FY2026 — Q1 FY2026 of 38.5% benefits from contingent timing; Q2 FY2026 will be a cleaner test of underlying margin trajectory against the 32–37% long-term band
Effective tax rate trajectory — Q1 FY2026 ran at 22.8% vs. the prior FY guide of 24–25%; with the FY guide not explicitly reaffirmed this quarter, watch whether Q2 brings a refreshed range or sustained run-rate below the prior band
AI productivity quantification — Powell put 25% submission automation and 50k hours on the table; watch whether Q2 FY2026 brings a margin or expense ratio data point that anchors the AI thesis with reported numbers rather than aspirational ones
Pharmacy consulting headwind duration — guided as "next couple of quarters" at 50–100bps to Retail; watch whether Q3 or Q4 FY2026 brings explicit roll-off confirmation or extension
Sources
- Brown & Brown Q1 FY2026 press release (Exhibit 99.1, SEC filing): https://www.sec.gov/Archives/edgar/data/79282/000119312526182375/bro-ex99_1.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.